Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Etelcalcetide
Drug ID BADD_D02514
Description Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Indications and Usage Etelcalcetide is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Marketing Status Not Available
ATC Code H05BX04
DrugBank ID DB12865
KEGG ID D10676
MeSH ID C583569
PubChem ID 71511839
TTD Drug ID D07RYI
NDC Product Code 55513-740; 55463-0030; 52076-6227; 55513-742; 55513-741
Synonyms etelcalcetide hydrochloride | velcalcetide | etelcalcetide | KAI-4169 | Parsabiv | AMG-416 | AMG 416
Chemical Information
Molecular Formula C38H73N21O10S2
CAS Registry Number 1262780-97-1
SMILES CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN= C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebral infarction17.08.01.004; 24.04.06.0020.009638%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.009638%Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.02.08.0030.038552%Not Available
Colon cancer16.13.01.001; 07.21.01.0010.001257%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Death08.04.01.001--
Diarrhoea07.02.01.0010.142159%
Disorientation19.13.01.002; 17.02.05.0150.007228%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.053009%
Drug hypersensitivity10.01.01.001--Not Available
Dysgeusia17.02.07.003; 07.14.03.0010.016866%
Dyspepsia07.01.02.0010.009638%
Dyspnoea22.02.01.004; 02.01.03.002--
Eczema23.03.04.0060.007228%
Electrocardiogram QT prolonged13.14.05.0040.016866%
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.0140.026504%Not Available
Feeling hot08.01.09.0090.009638%Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Flatulence07.01.04.0020.004819%
Fluid overload14.05.06.001; 02.05.04.0040.004819%Not Available
Flushing08.01.03.025; 24.03.01.002; 23.06.05.003--
Fracture15.08.02.001; 12.04.02.0010.004819%
Gait disturbance17.02.05.016; 08.01.02.002--
Gallbladder cancer16.07.05.001; 09.04.02.0050.001257%Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages